Association of ABCG2 421G>T (rs2231142) Polymorphism with rosuvastatin induced adverse effects in dyslipidemic patients: Implication for personalized medicine
PLOS One · 17.10.2025 · 20 (10) · e0334600
DOI: 10.1371/journal.pone.0334600 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 17.10.2025. Verfasst von Mahjabeen Sharif und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Therapeutics, Army Medical College Rawalpindi, National University of Medical Sciences, Rawalpindi, Pakistan. Hauptthemen laut MEDLINE: Rosuvastatin Calcium, ATP Binding Cassette Transporter, Subfamily G, Member 2, Polymorphism, Single Nucleotide, Neoplasm Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Statins are considered as the first line drugs for the treatment of hyperlipidemia. Despite proven efficacy of rosuvastatin, inter-individual variations in plasma rosuvastatin levels have been documented in various studies which causes variable response to statin tolerance. This study aims to evaluate the possible association of ABCG2 421 G > T (rs2231142) polymorphism with inter-individual variations in plasma rosuvastatin levels which potentially increases the rosuvastatin related adverse effects. This quasi experimental study was carried out from June 2022 till December 2023 in two tertiary care hospitals of Pakistan. Hyperlipidemic patients with low density lipoprotein more than 130 mg/dl were enrolled through non-probability purposive sampling. All the enrolled patients were treated with rosuvastatin 10 mg once daily for 12 weeks. Fasting lipid profile, serum creatine phosphokinase, liver and renal function tests were measured at the start of study and after 12 weeks of intervention with rosuvastatin. Blood samples were also collected for genotyping and determination of plasma rosuvastatin levels. Frequency of ABCG2 421 G > T polymorphism for wild type GG, heterozygous mutant GT and homozygous mutant TT genotypes were 54.5, 36.2 and 9.3% respectively. Minor allele frequency was 0.27. Patients with TT and GT genotypes have significantly raised plasma levels of rosuvastatin with mean value of 30.23 ± 4.8 ng/mL and 22.35 ± 5.1 ng/mL respectively as compared to wild GG genotypes 13.95 ± 8.9 ng/mL ( p =
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Therapeutics, Army Medical College Rawalpindi, National University of Medical Sciences, Rawalpindi, Pakistan.
- Department of Pharmacology and Therapeutics, CMH Institute of Medical Sciences, Bahawalpur, National University of Medical Sciences, Rawalpindi, Pakistan.
- Premier Research and Innovative Management (PRIME), Islamabad, Pakistan.
- Department of Pathology, National University of Medical Sciences, Rawalpindi, Pakistan.
- Armed Forces Institute of Cardiology & National Institute of Heart Diseases, Rawalpindi, Pakistan.
ORCID-Profile: Mahjabeen Sharif, Muhammad Bilal Siddique
Zitieren
APA
Sharif, M., Farhat, K., Noor, M., Ahmad, A. M., Khan, D. A., Afzal, R. K., & Siddique, M. B. (2025). Association of ABCG2 421G>T (rs2231142) Polymorphism with rosuvastatin induced adverse effects in dyslipidemic patients: Implication for personalized medicine. PLOS One, 20(10), e0334600. https://doi.org/10.1371/journal.pone.0334600
Vancouver
Sharif M, Farhat K, Noor M, Ahmad AM, Khan DA, Afzal RK, et al. Association of ABCG2 421G>T (rs2231142) Polymorphism with rosuvastatin induced adverse effects in dyslipidemic patients: Implication for personalized medicine. PLOS One. 2025;20(10):e0334600. doi:10.1371/journal.pone.0334600
BibTeX
@article{Sharif2025,
author = {Sharif, Mahjabeen and Farhat, Kulsoom and Noor, Mudassar and Ahmad, Ahsan Maqbool and Khan, Dilshad Ahmed and Afzal, Raja Kamran and Siddique, Muhammad Bilal},
title = {Association of ABCG2 421G>T (rs2231142) Polymorphism with rosuvastatin induced adverse effects in dyslipidemic patients: Implication for personalized medicine},
journal = {PLOS One},
year = {2025},
volume = {20},
number = {10},
pages = {e0334600},
doi = {10.1371/journal.pone.0334600}
}
EUVIMED